about
Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI.The Global Spine Care Initiative: a review of reviews and recommendations for the non-invasive management of acute osteoporotic vertebral compression fracture pain in low- and middle-income communities.The Global Spine Care Initiative: a systematic review of individual and community-based burden of spinal disorders in rural populations in low- and middle-income communities.The Global Spine Care Initiative: a narrative review of psychological and social issues in back pain in low- and middle-income communities.The Global Spine Care Initiative: a summary of guidelines on invasive interventions for the management of persistent and disabling spinal pain in low- and middle-income communities.The Global Spine Care Initiative: applying evidence-based guidelines on the non-invasive management of back and neck pain to low- and middle-income communities.The Global Spine Care Initiative: a summary of the global burden of low back and neck pain studies.The Global Spine Care Initiative: a systematic review for the assessment of spine-related complaints in populations with limited resources and in low- and middle-income communities.The Global Spine Care Initiative: World Spine Care executive summary on reducing spine-related disability in low- and middle-income communitiesThe Global Spine Care Initiative: care pathway for people with spine-related concernsThe Global Spine Care Initiative: classification system for spine-related concernsThe Global Spine Care Initiative: methodology, contributors, and disclosuresThe Global Spine Care Initiative: model of care and implementationThe Global Spine Care Initiative: resources to implement a spine care program
P50
Q40143100-F11B1E16-87CA-491F-91D2-A65CB49C5121Q45987902-D255B821-F4B6-4C58-8325-BD64CC43C9AAQ47241096-ECFD4979-1024-44F5-86C6-5D0A47B11CA8Q47552985-4D42BF7B-B96D-4F3D-AA9D-AF2AA12C85CAQ48265278-9A470476-CBD6-4930-9BA3-1F1F64BEED6DQ49827393-CAF91FC4-6CFD-4A85-AE4F-AE110C1E651BQ51767268-24264971-DA50-4111-B028-858CF7566941Q52680281-EF7EC7A1-91B0-4D4A-B398-8B97C667B4E6Q57761095-19DCA6D4-441D-4F6C-9F2D-87ED612C32B9Q57761103-40D83564-3353-49C3-8EDD-AC33AB9B3A94Q57761107-F93A0B37-BC30-4F6A-9FCA-FFDB6C453691Q57761111-D540145F-552B-478D-A50B-D519F5ED9E3DQ57761115-92E25AF0-00D5-43EF-8CEE-BF92E9AB281AQ57761120-0DF321BA-A388-442B-ADA0-97DDBB043061
P50
description
researcher
@en
name
Pierre Côté
@en
type
label
Pierre Côté
@en
prefLabel
Pierre Côté
@en
P31
P496
0000-0001-7227-6485